Drug Shortages and Stockpiling: What You Need to Know

Drug Shortages and Stockpiling: What You Need to Know

In recent years, drug shortages have become a major concern for healthcare systems around the world. The COVID-19 pandemic has only amplified this issue, as the demand for certain drugs has skyrocketed while the supply chain has been disrupted. This has resulted in shortages of essential medicines and has raised questions about how to prepare for such scenarios in the future.

According to a recent report by Reuters , Europe’s drug shortages may get even worse in the coming years. This is because of a combination of factors, including increased demand due to the aging population, supply chain disruptions, and issues with the pharmaceutical manufacturing process. The article also mentions that the COVID-19 pandemic has highlighted the need for more resilient supply chains and the need to better prepare for future crises.

So, what can be done to address the issue of drug shortages? One solution is to engage in stockpiling, or the act of building up a reserve of essential drugs. By having a stockpile of drugs on hand, healthcare systems can ensure that they have a sufficient supply even in the event of a crisis. However, this is easier said than done. Stockpiling drugs requires a significant investment, as well as careful planning and coordination. It is important to carefully consider the drugs that are most essential, the quantity that is needed, and the best way to store the drugs so that they remain effective.

Another factor to consider is the financial impact of stockpiling. The cost of stockpiling drugs can be substantial, and it is important to carefully weigh the benefits against the costs. Some countries have implemented stockpiling programs, while others have relied on the private sector to step in and provide drugs in the event of a shortage.

In conclusion, the issue of drug shortages is a complex and pressing problem that requires a multi-faceted approach. Stockpiling is one solution, but it requires careful consideration and investment. It is important to work together to find a solution that ensures that essential drugs are readily available in times of crisis and that the health and well-being of patients is protected.

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Read More »

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »

Lower Cost Prescription Drugs from Canada, Is It Legal?

In the early 2000s, the FDA set up guidelines in the Regulatory Procedures Manual (RPM) that permitted prescription drugs to be imported from other countries if the patient met very strict guidelines. Just stating that the patient needed the drug due to cost savings was not a justification to obtain the drug.

Read More »